GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 943
- Registration Number
- NCT04318548
- Locations
- 🇮🇹
GSK Investigational Site, Milano, Italy
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 29
- Registration Number
- NCT04316585
- Locations
- 🇵🇱
GSK Investigational Site, Lodz, Poland
Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 38
- Registration Number
- NCT04311463
- Locations
- 🇲🇽
GSK Investigational Site, Monterrey, Nuevo León, Mexico
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT04292912
- Locations
- 🇳🇿
GSK Investigational Site, Christchurch, New Zealand
Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT04276233
- Locations
- 🇮🇳
GSK Investigational Site, Pune, India
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 494
- Registration Number
- NCT04246047
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, United Kingdom
Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)
- Conditions
- Interventions
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1606
- Registration Number
- NCT04187144
- Locations
- 🇵🇱
GSK Investigational Site, Warszawa, Poland
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT04177823
- Locations
- 🇨🇳
GSK Investigational Site, Jiang Su Province, China
Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
- Conditions
- Interventions
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT04179032
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response
- Conditions
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 68
- Registration Number
- NCT04176939
- Locations
- 🇨🇳
GSK Investigational Site, Taoyuan, Taiwan